Summit Therapeutics shares are trading higher after the company announced hat data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented at the 2024 ESMO Annual Meeting.
Portfolio Pulse from Benzinga Newsdesk
Summit Therapeutics shares rose following the presentation of data on their investigational bispecific antibody, ivonescimab, at the 2024 ESMO Annual Meeting.
September 16, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Summit Therapeutics' stock price increased after the company presented promising data on ivonescimab, a potential first-in-class bispecific antibody, at the 2024 ESMO Annual Meeting.
The presentation of ivonescimab data at a major medical conference like ESMO suggests significant progress in Summit Therapeutics' research, likely boosting investor confidence and driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100